BRAFV600E patient derived colon cancer organoids identify biomarkers of response to EGFR and BRAF inhibition and replicate clinical data - PubMed
5 hours ago
- #Colorectal Cancer
- #BRAF V600E
- #Patient-Derived Organoids
- BRAFV600E patient-derived colon cancer organoids identified biomarkers for response to EGFR and BRAF inhibitors.
- The study replicated clinical data to validate organoid models as a reliable tool for predicting treatment outcomes.
- Biomarkers linked to drug resistance and response pathways like AKT, PI3K, PTEN, and ROS were explored.
- Ethical approvals were obtained from Charité Universitätsmedizin Berlin for patient consent and biobanking.
- Authors reported diverse competing interests, including funding from pharmaceutical companies and advisory roles.
- The research supports the use of organoids in personalized cancer therapy and biomarker discovery.